Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT04710498
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg

Study Details

The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.

Key Dates

Start date
Jun 22, 2021
Status verified
Jan 2025
Primary completion
Feb 7, 2024
Completion
Feb 15, 2024

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab
    Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.

Primary Outcome Measure

Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection [ Time Frame: 9 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94304-

Find similar trials in Stanford, CA

By condition
Skin cancer
By specialty
OncologySkin cancerDermatology
By research site
Stanford University· Stanford, CA

Related Studies